The histamine H3 receptor as a therapeutic drug target for metabolic disorders: Status, challenges and opportunities

Current Topics in Medicinal Chemistry

Volumn 11, Issue 12, 2011, Pages 1430-1446

  Plancher, Jean Marc ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Clinical trials; Histamine 3; Inverse agonist; Metabolic diseases; Obesity; Pharmacophore model; Protean agonist; Safety

Indexed keywords

5 CYCLOHEXYL 1 [4 (4 IMIDAZOLYL) 1 PIPERIDYL] 1 PENTANONE; A 331440; A 417022; A 423579; ANTIHISTAMINIC AGENT; ANTIOBESITY AGENT; CETIRIZINE; CIPRALISANT; CIPROXIFAN; CLOBENPROPIT; DESLORATADINE; DIPHENHYDRAMINE; FEXOFENADINE; FUB 181; GT 2394; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LORATADINE; LORCASERIN; NNC 381049; NNC 381202; PHENTERMINE PLUS TOPIRAMATE; PRAMLINTIDE; PROXIFAN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIOPERAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANXIETY DISORDER; APPETITE; COGNITIVE DEFECT; DEPRESSION; DESENSITIZATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; HAY FEVER; HUMAN; METABOLIC DISORDER; MOTION SICKNESS; NARCOLEPSY; NEUROMODULATION; NONHUMAN; OBESITY; PATENT; PATIENT COMPLIANCE; PEPTIC ULCER; PHARMACOLOGICAL BLOCKING; PHARMACOPHORE; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; URTICARIA; WEIGHT GAIN; DRUG DESIGN; DRUG EFFECT;

DRUG DESIGN; HISTAMINE ANTAGONISTS; HUMANS; METABOLIC DISEASES; RECEPTORS, HISTAMINE H3;

EID: 79959959298     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795860906     Document Type: Review

References (160)

1. Neel, J. V. Diabetes mellitus a 'thrifty' genotype rendered detrimental by 'progress'? Am. J. Hum. Genet., 1962, 14, 352-353.
2. Siervo, M.; Wells, J. C. K.; Cizza, G. The contribution of psychosocial stress to the obesity epidemic: An evolutionary approach. Horm. Metab. Res., 2006, 41, 261-270.
3. Speakman, J. R. Thrifty genes for obesity, an attractive but flawed idea, and an alternative perspective: the "drifty gene" hypothesis. Int. J. Obes., 2008, 32, 1611-1617.
4. Halford, J. C. G. Obesity drugs in clinical development. Curr. Op. Invest. Drugs, 2006, 7, 312-318.
5. Center for Disease Control and Prevention; U.S. Department of Health and Human Services (http://www.cdc.gov/).
6. Mokdad, A. H.; Ford, E. S.; Bowman, B. A.; Dietz, W. H.; Vinicor, F.; Bales, V. S.; Marks, J. S. Prevalence of obesity, diabetes, and obesity-related health risk factors. J. Am. Med. Assoc., 2003, 289, 76-79.
7. 2
8. Peeters, A; Barendregt, J. J.; Willekens, F.; Mackenback J.P.; Al Mamun, A.; Bonneux, L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann. Intern. Med., 2003, 138, 24-32.
9. Halford, J. C. G. Obesity drugs in clinical development. Curr. Op. Invest. Drugs, 2006, 7, 312-318.
10. Padwal, R. S.; Majumdar, S. R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet, 2007, 369, 71-77.
11. st, 2010, http://www.ema.europa.eu/
12. Finkelstein, E. A.; Fiebelkorn, I. C.; Wang, G. J. State-level estimates of annual medical expenditures attributable to obesity. Obest. Res., 2004, 12, 18-24.
13. Jones, D. Novel pharmacotherapies for obesity poised to enter market. Nature, 2009, 8, 833-834.
14. Schwartz, J. C.; Arrang, J. M.; Garbarg, M.; Pollard, H.; Rut, M. Histaminergic transmission in mammalian brain. Physiol. Rev., 1991, 71, 1-51.
15. Brown, R. E.; Steven, D. R.; Hass, H. L. The physiology of brain histamine. Prog. Neurobiol., 2001, 63, 637-672.
16. Moya-Garcia, A. A.; Pino-Angeles, A.; Gil-Redondo, R.; Morreale, A.; Sanchez-Jimenez, F. Structural features of mammalian histidine decarboxylase reveal the basis for specific inhibition. Brit. J. Pharm., 2009, 157, 4-13.
17. Fueloep, A. K.; Foeldes, A.; Buzas, E.; Hegyi, K.; Miklos, I. H.; Romics, L.; Kleiber, M.; Nagy, A.; Falus, A.; Kovacs, K. J. Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene. Endocrinology, 2003, 144, 4306-4314.
18. Jorgensen, E. A.; Vogelsang, T. W.; Knigge, U.; Watanabe, T.; Warberg, J.; Kjaer, A. Increased susceptibility to diet-induced obesity in histamine-deficient mice. Neuroendocrin. 2006, 83, 289-294.
19. Hough, L. B.; Khandelwal, J. K.; Green, J. P. Inhibition of brain histamine metabolism by metoprine. Biochem. Pharm., 1986, 35, 307-310.
20. Yamashita, M.; Fukui, H.; Sugama, K.; Horio, Y.; Ito, S.; Mizuguchi, H.; Wada, H. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc. Nat. Acad. Scie. USA, 1991, 88, 11515-11519.
21. For example, see Bernstein, D. I.; Schoenwetter, W. F.; Nathan, R. A.; Storms, W.; Ahlbrandt, R.; Mason, J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann. Allerg. Asthm. Immun., 1997, 79, 443-448.
22. Harada, M.; Terai, M.; Maeno, H. Effect of a new potent H2-receptor antagonist 3[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric mucosal histamine-sensitive adenylate cyclase from guinea pig. Bio. Pharm., 1983, 32, 1635-1640.
23. Liu, C.; Ma, X.-J.; Jiang, X.; Wilson, S. J.; Hofstra, C. L.; Blevitt, J.; Pyati, J.; Li, X.; Chai, W.; Carruthers, N.; Lovenberg, T. W. Cloning and Pharmacological Characterization of a Fourth Histamine Receptor (H4) Expressed in Bone Marrow. Mol. Pharmacol., 2001, 59, 420-426.
24. Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y. Matsumoto, S.-I. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem., 2000, 275, 36781-36786.
25. Liu, C.; Ma, X.-J.; Jiang, X.; Wilson, S. J.; Hofstra, C. L.; Blevitt, J.; Pyati, J.; Li, X.; Chai, W.; Carruthers, N.; Lovenberg, T. W. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharm., 2001, 59, 420-426.
26. Morse, K. L.; Behan, J.; Laz, T. M.; West, R. E.; Greenfeder, S. A.; Anthes, J. C.; Umland, S.; Wan, Y.; Hipkin, R. W.; Gonsiorek, W.; Shin, N.; Gustafson, E. L.; Qiao, X.; Wang, S.; Hedrick, J. A.; Greene, J.; Bayne, M.; Monsma, F. J. Jr. Cloning and characterization of a novel human histamine receptor. J. Pharm. Exp. Ther., 2001, 296, 1058-1066.
27. Zhu, Y.; Michalovich, D.; Wu, H.-L.; Tan, K. B.; Dytko, G. M.; Mannan, I. J.; Boyce, R.; Alston, J.; Tierney, L. A.; Li, X.; Herrity, N. C.; Vawter, L.; Sarau, H. M.; Ames, R. S.; Davenport, C. M.; Hieble, J. P.; Wilson, S.; Bergsma, D. J.; Fitzgerald, L. R. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol. Pharm., 2001, 59, 434-441.
28. Hough, L. B. Genomics meets histamine receptors: new subtypes, new receptors. Mol. Pharmacol., 2001, 59, 415-419.
29. de Esch, I. J. P.; Thurmond, R. L.; Jongejan, A.; Leurs, R. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol. Sci. 2005, 26, 462-469.
30. Leurs, R.; Chazot, P. L.; Shenton, F. C.; Lim, H. D.; de Esch, I. J. P. Molecular and biochemical pharmacology of the histamine H4 receptor. Brit. J. Pharm., 2009, 157, 14-23.
31. Zampeli, E.; Tiligada, E. The role of histamine H4 receptor in immune and inflammatory disorders. Brit. J. Pharm., 2009, 157, 24-33.
32. Kiss, R.; Keseru, G. M. Histamine H4 receptor ligands and their potential therapeutic applications. Exp. Opin. Ther. Pat., 2009, 19, 119-135.
33. Mercer, L. P.; Kelley, D. S.; Humphries, L. L.; Dunn, J. D. Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats. J. Nutr., 1994, 7, 1029-1036.
34. Lecklin, A.; Etu-Seppala, P.; Stark, H.; Tuomisto, L. Effects of intracerebroventricularly infused histamine and selective H1, H2, and H3 receptor agonists on food and water intake and urine flow in Wistar rats. Brain Res., 1998, 793, 279-288.
35. Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. Therapeutic potential of histamine H3-receptor agonists and antagonists. Trends Pharmacol. Sci., 1998, 19, 177-183.
36. Leurs, R.; Timmerman, H. The Histamine H3-Receptor: A Target for New Drugs. In: Pharmacochemistry Library, Elsevier: Amsterdam, 1998, Vol. 30.
37. Stark, H.; Arrang, J. M.; Ligneau, X.; Garbarg, M.; Ganellin, C. R.; Schwartz, J. C.; Schunack, W. The histamine H3-receptor and its ligands. In: Progress in Medicinal Chemistry; King, F. D., Oxford, A. W., Eds.; Elsevier: Amsterdam, 2001, 38, 279-309.
38. 3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Mol. Interventions, 2006, 6, 77-88.
39. Esbenshade, T. A.; Browman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, M. D.; Brioni, J. D. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Brit. J. Pharmacol., 2008, 154, 1-16.
40. Vohora, D.; Medhurst, A. D.; Carruthers, N. I.; Celanire, S.; Schwartz, J.-C.; Selbach, O.; Haas, H. L.; Panula, P.; Jin, C. Y.; Karlstedt, K.; Bakker, R.; Lebon, F.; Stark, H.; Coruzzi, G.; Adami, M.; Passani, M.; Blandina, P.; Brownan, K. E.; Fox, G. B.; Shelton, J. E.; Lovenberg, T. W.; Dugovc, C.; Esbenshade, T. A.; Brune, M. E.; Strakhova, M. I.; Pillai, K.; Browman, K. E.; Zhang, M.; Rueter, L. E.; Chazot, P.; Shenton, F. C. The third Histamine Receptor. Vohora, D. Eds.; CRC Press.: Boca Renton, 2009.
41. Bonaventure, P.; Letavic, M.; Dugovic, C.; Wilson, S.; Aluisio, L.; Pudiak, C.; Lord, B.; Mazur, C.; Kamme, F.; Nishino, S.; Carruthers, N.; Lovenberg, T. Histamine H3 receptor antagonists: From target identification to drug leads. Biochem. Pharm., 2007, 73, 1084-1096.
42. Sander, K.; Kottke, T.; Stark, H. Histamine H3 receptor antagonists go to clinics. Biol. Pharm. Bull., 2008, 31, 2163-2181.
43. Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J. P. Histamine H3 receptor antagonists reach out for the clinic. Drug Discov. Today, 2005, 10, 1613-1627.
44. Morimoto, T.; Yamamoto, Y.; Mobarakeh, J. I.; Yanai, K.; Watanabe, T.; Watanabe, T.; Yamatodani, A. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol. Behav., 1999, 67, 679-683.
45. Orthen-Gambill, N. Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharm. Bio. Behav., 1988, 3, 81-86.
46. Sakata, T.; Okuma, K.; Fukagawa, K.; Fujimoto, K.; Yoshimatsu, H.; Shiraishi, T.; Wada, H. Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation. Brain Res., 1988, 441, 403-407.
47. Kim, S. F.; Huang, A. S.; Snowman, A. M.; Teuscher, C.; Snyder, S. H. Antipsychotic drug-induced weight gain mediated by hista mine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Nat. Acad. Scie. USA, 2007, 104, 3456-3459.
48. Lecklin, A.; Etu-Seppala, P.; Stark, H.; Tuomisto, L. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Brain Res., 1998, 793, 279-288.
49. McIntyre, R. S.; Mancini, D. A.; Basile, V. S. Mechanisms of antipsychotic-induced weight gain. J. Clin. Psych., 2001, 62, 23-29,
50. Kroeze, W. K.; Hufeisen, S. J.; Popadak, B. A.; Renock, S. M.; Steinberg, S. A.; Ernsberger, P.; Jayathilake, K.; Meltzer, H. Y.; Roth, B. L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharm, 2003, 28, 519-526.
51. Van Ganse, E.; Kaufman, L.; Derde, M. P.; Yernault, J. C.; Delaunois, L.; Vincken, W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur. Resp. J., 1997, 10, 2216-2224.
52. Horak, F.; Stubner, U. P. Comparative tolerability of second generation antihistamines. Drug Safety, 1999, 20, 385-401.
53. Chapman, I.; Parker, B.; Doran, S.; Feinle-Bisset, C.; Wishart, J.; Strobel, S.; Wang, Y.; Burns, C.; Lush, C.; Weyer, C.; Horowitz, M. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia, 2005, 48, 838-848.
54. Barak, N. Compositions comprising H1-receptor agonist for weight management. U.S. Pat. Appl. Publ., 2006, US 2006148787 A1.
55. 3 receptor. Mol. Pharmacol., 1999, 55, 1101-1107.
56. Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature, 1983, 302, 832-837.
57. Parsons, M. E.; Ganellin, C. R. Histamine and its receptors. Br. J. Pharmacol., 2006, 147, S127.
58. Karlstedt, K.; Ahman, M. J.; Anichtchik, O. V.; Soinila, S.; Panula, P. Expression of the H3 receptor in the developing CNS and brown fat suggests novel roles for histamine. Mol. Cell. Neuroscie., 2003, 24, 614-622.
59. Collins, S.; Cao, W.; Robidoux, J. Learning new tricks from old dogs: α-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol. Endo., 2004, 18, 2123-2131.
60. Bongers, G.; Krueger, K. M.; Miller, T. R.; Baranowski, J. L.; Estvander, B. R.; Witte, D. G.; Strakhova, M. I.; van Meer, P.; Bakker, R. A.; Cowart, M. D.; Hancock, A. A.; Esbenshade, T. A.; Leurs, R. An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity. J. Pharm. Exp. Ther., 2007, 323, 888-898.
61. Esbenshade, T. A.; Krueger, K. M.; Yao, B. B.; Witte, D. G.; Estvander, B. R.; Baranowski, J. L.; Miller, T. R.; Hancock, A. A. Differences in pharmacological properties of histamine H(3) receptor agonists and antagonists revealed at two human H(3) receptor isoforms. Poster at the European Histamine Research Society Congress 2006.
62. Bakker, R. A.; Lozada, A. F.; van Marle, A.; Shenton, F. C.; Drutel, G.; Karlstedt, K.; Hoffmann, M.; Lintunen, M.; Yamamoto, Y.; van Rijn, R. M.; Chazot, P. L.; Panula, P.; Leurs, R. Discovery of naturally occurring splice variants of the rat histamine H3 receptor that act as dominant-negative isoforms. Mol. Pharmacol., 2006, 69, 1194-1206.
63. Strakhova, M. I.; Fox, G. F.; Carr, T. L.; Witte, D. G.; Vortherms, T. A.; Manelli, A. M.; Miller, T. R.; Yao, B. B.; Brioni, J. D.; Esbenshade, T. A. Cloning and characterization of the monkey histamine H3 receptor isoforms. Eur. J. Pharm., 2008, 601, 8-15.
64. Bakker, R. A. Histamine H3-receptor isoforms. Inflamm. Res., 2004, 53, 509-516.
65. Hancock, A. A.; Esbenshade, T. A.; Krueger, K. M.; Yao, B. B. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci., 2003, 73, 3043-3072.
66. Barbier, A. J.; Bradbury, M. J. Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders. CNS & Neuro. Dis. 2007, 6, 31-43.
67. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharm. Sci., 2004, 25, 618-625.
68. 3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Bio. Pharm., 2007, 73, 1157-1171.
69. Gemkow, M. J.; Davenport, A. J.; Harich, S.; Ellenbroek, B. A.; Cesura, A.; Hallett, D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today, 2009, 14, 509-515.
70. Hancock, A. A. H3 receptor antagonists/inverse agonists as anti-obesity agents. Curr. Op. Invest. Drugs, 2003, 4, 1190-1197.
71. Hancock, A. A.; Brune, M. E. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Exp. Opin. Invest. Drugs, 2005, 14, 223-241.
72. Malmlof, K.; Hohlweg, R.; Rimvall, K. Targeting of the central histaminergic system for treatment of obesity and associated metabolic disorders. Drug Dev. Res., 2006, 67, 651-665.
73. Tokita, S.; Takahashi, K.; Kotani, H. Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J. Pharm. Sci., 2006, 101, 12-18.
74. rd Ed., 2008, 395-403.
75. Hill, S. J. Histamine receptors branch out. Nature 1987, 327, 104-105.
76. Arrang, J. M.; Garbarg, M.; Lancelot, J. C.; Lecomte, J. M.; Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J. C. Highly potent and selective ligands for histamine H3-receptors. Nature, 1987, 327, 117-123.
77. Sakata, T.; Ookuma, K.; Fujimoto, K.; Fukagawa, K.; Yoshimatsu, H. Histaminergic control of energy balance in rats. Brain Res. Bull., 1991, 27, 371-375.
78. Itoh, E.; Fujimiya, M.; Inui, A. Thioperamide, a histamine H3 receptor antagonist, suppresses NPY-but not Dynorphin A-induced feeding in rats. Regul. Pept., 1998, 75-76, 373-376.
79. Sindelar, D. K.; Shepperd, M. L.; Pickard, R. T.; Alexander-Chacko, J.; Dill, M. J.; Cramer, J. W.; Smith, D. P.; Gadski, R. Central H3R activation by thioperamide does not affect energy balance. Pharm. Bio. Behav., 2004, 78, 275-283.
80. Mollet, A.; Lutz, T. A.; Meier, S.; Riediger, T.; Rushing, P. A.; Scharrer, E. Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am. J. Physio., 2001, 281, R1442-R1448.
81. Takahashi, K.; Suwa, H.; Ishikawa, T.; Kotani, H. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J. Clin. Invest., 2002, 110, 1791-1799.
82. Stark, H.; Sippl, W.; Ligneau, X.; Arrang, J.-M.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W. Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg. Med. Chem. Lett., 2001, 11, 951-954.
83. Liu, C.; Wilson, S. J.; Kuei, C.; Lovenberg, T. W. Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J. Pharm. Exp. Ther., 2001, 299, 121-130.
84. Hancock, A. A.; Bennani, Y. L.; Bush, E. N.; Esbenshade, T. A.; Faghih, R.; Fox, G. B.; Jacobson, P.; Knourek-Segel, V.; Krueger, K. M.; Nuss, M. E.; Pan, J. B.; Shapiro, R.; Witte, D. G.; Yao, B. B. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. Eur. J. Pharm., 2004, 487,
85. Wieland, K.; Bongers, G.; Yamamoto, Y.; Hashimoto, T.; Yamatodani, A.; Menge, W. M. B. P.; Timmerman, H.; Lovenberg, T. W.; Leurs, R. Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H3 antagonists. J. Pharm. Exp. Ther., 2001, 299, 908-914.
86. Gbahou, F.; Rouleau, A.; Morisset, S.; Parmentier, R.; Crochet, S.; Lin, J.-S.; Ligneau, X.; Tardivel-Lacombe, J.; Stark, H.; Schunack, W.; Ganellin, C. R.; Schwartz, J.-C.; Arrang, J.-M. Protean agonism at histamine H3 receptors in vitro and in vivo. Proc. Nat. Acad. Scie. USA, 2003, 100, 11086-11091.
87. Baldi, E.; Bucherelli, C.; Schunack, W.; Cenni, G.; Blandina, P.; Passani, M. B. The H3 receptor protean agonist proxyfan enhances the expression of fear memory in the rat. Neuropharm., 2005, 48, 246-251.
88. Huels, A.; Purand, K.; Stark, H.; Reidemeister, S.; Ligneau, X.; Arrang, J.-M.; Schwartz, J.-C.; Schunack, W. Novel histamine H3-receptor antagonists with benzyl ether structure or related moieties. Synthesis and structure-activity relationships. Arch. Pharm., 1996, 329, 379-385.
89. Ligneau, X.; Garbarg, M.; Vizuete, M. L.; Diaz, J.; Purand, K.; Stark, H.; Schunack, W.; Schwartz, J.-C. [125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors. J. Pharm. Exp. Ther., 1994, 271, 452-459.
90. Stark, H.; Purand, K.; Huels, A.; Ligneau, X.; Garbarg, M.; Schwartz, J.-C.; Schunack, W. [125I]Iodoproxyfan and related compounds: A reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor. J. Med. Chem., 1996, 39, 1220-1226.
91. Ito, S.; Yoshimoto, R.; Miyamoto, Y.; Mitobe, Y.; Nakamura, T.; Ishihara, A.; MacNeil, D. J.; Kanatani, A.; Tokita, S. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor. Eur. J. Pharm., 2006, 529, 40-46.
92. Liu, H.; Kerdesky, F. A.; Black, L. A.; Fitzgerald, M.; Henry, R.; Esbenshade, T. A.; Hancock, A. A.; Bennani, Y. L. An efficient multigram synthesis of the potent histamine H3 antagonist GT-2331 and the reassessment of the absolute configuration. J. Org. Chem., 2004, 69, 192-194.
93. Minick, D. J.; Copley, R. C. B.; Szewczyk, J. R.; Rutkowske, R. D.; Miller, L. A. An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism. Chirality, 2007, 19, 731-740.
94. Halpern, M. T. GT-2331. Curr. Opin. Central Periph. Nerv. Syst. Invest. Drugs, 1999, 1, 524-527.
95. Durant, G. J.; Khan, A. M.; Tedford, C. E. Piperidylimidazole histamine H3-receptor antagonists and therapeutic uses. U.S. Pat. Appl. US5486526A, 1996.
96. Yates, S. L.; Powlowski, G. P.; Babu, J. S.; Rajagopalan, R.; Wawro, W. J.; Tedford, C. E. Inverse agonists of the histamine-3 receptor as appetite suppressants. Abstr. Papers, 225th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003.
97. Yates, S. L.; Pawlowski, G. P.; Antal, J. M.; Ali, S. M.; Jiang, J.; Brunden, K. R. Effects of a novel histamine H3 receptor antagonist, GT-2394, on food intake and weight gain in Sprague-Dawley rats. Soc. Neurosci. Abstract, 2000, 26, 102.10.
98. Yang, R.; Hey, J. A.; Aslanian, R.; Rizzo, C. A. Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology, 2002, 66, 128-135.
99. Silva, C.; Mor, M.; Bordi, F.; Rivara, S.; Caretta, A.; Ballabeni, V.; Barocelli, E.; Plazzi, P. V. Plasma concentration and brain penetration of the H3-receptor antagonist thioperamide in rats. Farmaco., 1997, 52, 457-462.
100. Meier, G.; Apelt, J.; Reichert, U.; Grassmann, S.; Ligneau, X.; Elz, S.; Leurquin, F.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W.; Stark, H. Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur. J. Pharm. Sci., 2001, 13, 249-259.
101. Ligneau, X.; Perrin, D.; Landais, L.; Camelin, J.-C.; Calmels, T. P. G.; Berrebi-Bertrand, I.; Lecomte, J.-M.; Parmentier, R.; Anaclet, C.; Lin, J.-S.; Bertaina-Anglade, V.; Drieu la Rochelle, C.; d'Aniello, F.; Rouleau, A.; Gbahou, F.; Arrang, J.-M.; Ganellin, C. R.; Stark, H.; Schunack, W.; Schwartz, J.-C. BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J. Pharm. Exp. Ther., 2007, 320, 365-375.
102. Swanson, D. M.; Wilson, S. J.; Boggs, J. D.; Xiao, W.; Apodaca, R.; Barbier, A. J.; Lovenberg, T. W.; Carruthers, N. I. Aplysamine-1 and related analogs as histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 897-900.
103. Faghih, R.; Dwight, W.; Vasudevan, A.; Dinges, J.; Conner, S. E.; Esbenshade, T. A.; Bennani, Y. L.; Hancock, A. A. Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands. Bioorg. Med. Chem. Lett., 2002, 12, 3077-3079.
104. Hancock, A. A.; Diehl, M. S.; Faghih, R.; Bush, E. N.; Krueger, K. M.; Krishna, G.; Miller, T. R.; Wilcox, D. M.; Nguyen, P.; Pratt, J. K.; Cowart, M. D.; Eshenshade, T. A.; Jacobson, P. B. In vitro optimization of structure activity relationships of analogs of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. Basic Clin. Pharm. Tox., 2004, 95, 144-152.
105. Hancock, A. A.; Diehl, M. S.; Fey, T. A.; Bush, E. N.; Faghih, R.; Miller, T. R.; Krueger, K. M.; Pratt, J. K.; Cowart, M. D.; Dickinson, R. W.; Shapiro, R.; Knourek-Segel, V. E.; Droz, B. A.; McDowell, C. A.; Krishna, G.; Brune, M. E.; Esbenshade, T. A.; Jacobson, P. B. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy. Inflamm. Res., 2005, 54, S27-S29.
106. Malmlof, K.; Zaragoza, F.; Golozoubova, V.; Refsgaard, H. H. F.; Cremers, T.; Raun, K.; Wulff, B. S.; Johansen, P. B.; Westerink, B.; Rimvall, K. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight. Int. J. Obesity, 2005, 29, 1402-1412.
107. Peschke, B.; Bak, S.; Hohlweg, R.; Pettersson, I.; Refsgaard, H.; Hoffmann, F.; Viuff, D.; Rimvall, K. Cinnamic amides of (S)-2-(aminomethyl)pyrrolidines are potent H3 antagonists. Bioorg. Med. Chem., 2004, 12, 2603-2616.
108. Malmlof, K.; Golozoubova, V.; Peschke, B.; Wulff, B. S.; Refsgaard, H. H. F.; Johansen, P. B.; Cremers, T.; Rimvall, K. Increase of neuronal histamine in obese rats is associated with decreases in body weight and plasma triglycerides. Obesity, 2006, 14, 2154-2162.
109. Malmlof, K.; Hastrup, S.; Wulff, B.; Hansen, B. C.; Peschke, B.; Jeppesen, C.; Hohlweg, R.; Rimvall, K. Antagonistic targeting of the histamine H3 receptor decreases caloric intake in higher mammalian species. Biochem. Pharm., 2007, 73, 1237-1242.
110. Pierson-David, P.; Fettes, A.; Freichel, C.; Gatti-McArthur, S.; Hertel, C.; Huwyler, J.; Mohr, P.; Nakagawa, T.; Nettekoven, M.; Plancher, J.-M.; Raab, S.; Richter, H.; Roche, O.; Rodriguez Sarmiento, R. M.; Schmitt, M.; Schuler, F.; Takahashi, T.; Taylor, S.; Ullmer, C.; Wiegand, R. 5-Hydroxyindole-2-carboxylic Acid Amides: Novel Histamine-3 Receptor Inverse Agonists for the Treatment of Obesity. J. Med. Chem., 2009, 52, 3855-3868.
111. Ballesteros, J. A.; Weinstein, Harel. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neuroscie., 1995, 25, 366-428.
112. Roche, O.; Nettekoven, M.; Vifian, W.; Rodriguez Sarmiento, R. M. Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists. Bioorg. Med. Chem. Lett., 2008, 18, 4377-4379.
113. Roche, O.; Rodriguez Sarmiento, R. M. A new class of histamine H3 receptor antagonists derived from ligand based design. Bioorg. Med. Chem. Lett., 2007, 17, 3670-3675.
114. 3R based on rhodopsin (1F88). Ten intermediates were generated and the best model was selected. No minimization was performed to keep the backbone coordinates of the crystallographic structure. All molecules were then manually docked into the membrane cavity. The binding site was defined as the set of amino acids found at 6.0Å away from the retinal in the X-ray structure of rhodopsin.
115. Stark, H.; Sippl, W.; Ligneau, X.; Arrang, J.-M.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W. Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg. Med. Chem. Lett., 2001, 11, 951-954.
116. Kratochwil, N. A.; Malherbe, P.; Lindemann, L.; Ebeling, M.; Hoener, M. C.; Muehlemann, A.; Porter, R. H. P.; Stahl, M.; Gerber, P. R. An Automated system for the analysis of g proteincoupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application. J. Chem. Inf. Model., 2005, 45, 1324-1336.
117. Schlegel, B.; Laggner, C.; Meier, R.; Langer, T.; Schnell, D.; Seifert, R.; Stark, H.; Hoeltje, H.-D.; Sippl, W. Generation of a homology model of the human histamine H3 receptor for ligand docking and pharmacophore-based screening. J. Comp.-Aid. Mol. Des., 2007, 21, 437-453.
118. Pan, J. B.; Yao, B. B.; Miller, T. R.; Kroeger, P. E.; Bennani, Y. L.; Komater, V. A.; Esbenshade, T. A.; Hancock, A. A.; Decker, M. W.; Fox, G. B. Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121. Life Sci., 2006, 79, 1366-1379.
119. Zaragoza, F.; Stephensen, H.; Peschke, B.; Rimvall, K. 2-(4-Alkyl-1-piperazinyl)quinolines as a New Class of Imidazole-Free Histamine H3 Receptor Antagonists. J. Med. Chem., 2005, 48, 306-311.
120. Esbenshade, T. A.; Fox, G. B.; Krueger, K. M.; Baranowski, J. L.; Miller, T. R.; Kang, C. H.; Denny, L. I.; Witte, D. G.; Yao, B. B.; Pan, J. B.; Faghih, R.; Bennani, Y. L.; Williams, M.; Hancock, A. A. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Bio. Pharm., 2004, 68, 933-945.
121. Hancock, A. A. The Challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H3 antagonists/ inverse agonists. Bio. Pharm., 2006, 71, 1103-1113.
122. Barbier, A. J.; Berridge, C.; Dugovic, C.; Laposky, A. D.; Wilson, S. J.; Boggs, J.; Aluisio, L.; Lord, B.; Mazur, C.; Pudiak, C. M.; Langlois, X.; Xiao, W.; Apodaca, R.; Carruthers, N. I.; Lovenberg, T. W. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Brit. J. Pharm., 2004, 143, 649-661.
123. Fox, G. B.; Pan, J. B.; Esbenshade, T. A.; Bennani, Y. L.; Black, L. A.; Faghih, R.; Hancock, A. A.; Decker, M. W. Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav. Brain Res., 2002, 131, 151-161.
124. Sumner, B. E.; Cruise, L. A.; Slattery, D. A.; Hill, D. R.; Shahid, M.; Henry, B. Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharm., 2004, 171, 306-321.
125. Hancock, A. A.; Bitner, R. S.; Krueger, K. M.; Otte, S.; Nikkel, A. L.; Fey, T. A.; Bush, E. N.; Dickinson, R. W.; Shapiro, R.; Knourek-Segel, V.; Droz, B. A.; Brune, M. E.; Jacobson, P. B.; Cowart, M. D.; Esbenshade, T. A. Distinctions and contradistinctions between antiobesity histamine H3 receptor (H3R) antagonists compared to cognition-enhancing H3 receptor antagonists. Inflam. Res., 2006, 55, S42-S44.
126. Southam, E.; Cilia, J.; Gartlon, J. E.; Woolley, M. L.; Lacroix, L. P.; Jennings, C. A.; Cluderay, J. E.; Reavill, C.; Rourke, C.; Wilson, D. M.; Dawson, L. A.; Medhurst, A. D.; Jones, D. N. C. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharm, 2009, 201, 483-494.
127. Medhurst, A. D.; Atkins, A. R.; Beresford, I. J.; Brackenborough, K.; Briggs, M. A.; Calver, A. R.; Cilia, J.; Cluderay, J. E.; Crook, B.; Davis, J. B.; Davis, R. K.; Davis, R. P.; Dawson, L. A.; Foley, A. G.; Gartlon, J.; Gonzalez, M. I.; Heslop, T.; Hirst, W. D.; Jennings, C.; Jones, D. N. C.; Lacroix, L. P.; Martyn, A.; Ociepka, S.; Ray, A.; Regan, C. M.; Roberts, J. C.; Schogger, J.; Southam, E.; Stean, T. O.; Trail, B. K.; Upton, N.; Wadsworth, G.; Wald, J. A.; White, T.; Witherington, J.; Woolley, M. L.; Worby, A.; Wilson, D. M. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharm, Exper. Ther., 2007, 321, 1032-1045.
128. Powell, D. R. Obesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo. Obesity Rev., 2006, 7, 89-108.
129. Takahashi, K.; Suwa, H.; Ishikawa, T.; Kotani, H. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J. Clin. Invest., 2002, 110, 1791-1799.
130. Naruse, T.; Ishii, R. Relationship between histamine receptors in the brain and diazepam-induced hyperphagia in rats. Pharm. Bio. Behav., 1995, 51, 923-927.
131. Yoshimoto, R.; Miyamoto, Y.; Shimamura, K.; Ishihara, A.; Takahashi, K.; Kotani, H.; Chen, A. S.; Chen, H. Y.; MacNeil, D. J.; Kanatani, A.; Tokita, S. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proceed. Nat. Acad. Scie. USA, 2006, 103, 13866-13871.
132. Yoshimoto, R.; Kanatani, A.; Tokita, S. Distinctive role of central histamine H3 receptor in various orexigenic pathways. Eur. J. Pharm., 2008, 579, 229-232.
133. Yoshimoto, R.; Ishihara, A.; Kanatani, A.; Tokita, S. Histamine H3 agonists for use as therapeutic agent for lipid/carbohydrate metabolism disorder. PCT Int. Appl. WO2007032536 A1, 2007.
134. Sun, M.; Zhao, C.; Gfesser, G. A.; Thiffault, C.; Miller, T. R.; Marsh, K.; Wetter, J.; Curtis, M.; Faghih, R.; Esbenshade, T. A.; Hancock, A. A.; Cowart, M. Synthesis and SAR of 5-Amino-and 5-(Aminomethyl)benzofuran Histamine H3 Receptor Antagonists with Improved Potency. J. Med. Chem., 2005, 48, 6482-6490.
135. Rodriguez Sarmiento, R. M.; Nettekoven, M. H.; Taylor, S.; Plancher, J.-M.; Richter, H.; Roche, O. Selective naphthalene H3 receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs. Bioorg. Med. Chem. Lett., 2009, 19, 4495-4500.
136. Montenez, J. P.; Van Bambeke, F.; Piret, J.; Brasseur, R.; Tulkens, P. M.; Mingeot-Lecler183-197. cq, M. P. Interactions of macrolide antibiotics (erythromycin A, roxithromycin, erythromycylamine [dirithromycin], and azithromycin) with phospholipids: Computeraided conformational analysis and studies on acellular and cell culture models. Toxicol. Appl. Pharmacol., 1999, 156, 129-140.
137. Jia, L.; Sun, H. Support vector machines classification of hERG liabilities based on atom types. Bioorg. Med. Chem., 2008, 16, 6252-6260.
138. Raschi, E.; Vasina, V.; Poluzzi, E.; De Ponti, F. The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol. Res., 2008, 57, 181-195.
139. Waring, M. J.; Johnstone, C. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett., 2007, 17, 1759-1764.
140. Aronov, A. M. Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers. J. Med. Chem., 2006, 49, 6917-6921.
141. Imamura, M.; Seyedi, N.; Lander, H. M.; Levi, R. Functional identification of histamine H3-receptors in the human heart. Circulat. Res., 1995, 77, 206-210.
142. Silver, R. B.; Mackins, C. J.; Smith, N. C. E.; Koritchneva, I. L.; Lefkowitz, K.; Lovenberg, T. W.; Levi, R. Coupling of histamine H3 receptors to neuronal Na+/H+ exchange: a novel protective mechanism in myocardial ischemia. Proc. Nat. Acad. Scie. USA, 2001, 98, 2855-2859.
143. Study to Demonstrate Cognitive Enchancing Effects of BF2.649. 2009, http://clinicaltrials.gov/show/NCT00690274.
144. Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients. 2009, http://clinicaltrials.gov/show/NCT00642928.
145. Lin, J.-S.; Dauvilliers, Y.; Arnulf, I.; Bastuji, H.; Anaclet, C.; Parmentier, R.; Kocher, L.; Yanagisawa, M.; Lehert, P.; Ligneau, X.; Perrin, D.; Robert, P.; Roux, M.; Lecomte, J.-M.; Schwartz, J.-C. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin-/-mice and patients. Neurobio. Dis., 2008, 30, 74-83.
146. Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy. 2009, http://clinicaltrials.gov/show/NCT00366080.
147. Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy, 2009, http://clinicaltrials.gov/show/NCT00620659.
148. MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia, 2008, http://clinicaltrials.gov/show/NCT00506077.
149. A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD. 2008, http://clinicaltrials.gov/show/NCT00475735.
150. MK0249 for the Symptomatic Treatment of Alzheimer's Disease. 2009, http://clinicaltrials.gov/show/NCT00420420.
151. A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy. 2009, http://clinicaltrials.gov/show/NCT01006122.
152. A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD). 2009, http://clinicaltrials.gov/show/NCT00531752.
153. Pfizer pipeline. 2009, http://www.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf.
154. A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy. 2009, http://clinicaltrials.gov/show/NCT00424931.
155. Barak, N. Betahistine: what's new on the agenda? Exp. Op. Invest. Drugs, 2008, 17, 795-804.
156. The Effect of Betahistine on Body Weight in Obese Subjects. 2007, http://clinicaltrials.gov/show/NCT00409305.
157. Fossati, A.; Barone, D.; Benvenuti, C. Binding affinity profile of betahistine and its metabolites for central Fossati, A histamine receptors of rodents. Pharmacol. Res., 2001, 43, 389-392.
158. LCMS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers. Chen, X. Y.; Zhong, D. F.; Duan, J. L.; Yan, B. X. Xenobiotica, 2003, 33, 1261-1271.
159. Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Subjects. 2008, http://clinicaltrials.gov/show/NCT00642993.
160. Search on Scifinder© with "Histamine-3" as a keyword.